SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0000950170-24-088238
Filing Date
2024-07-31
Accepted
2024-07-31 07:15:28
Documents
76
Period of Report
2024-06-30

Document Format Files

Seq Description Document Type Size
1 10-Q fulc-20240630.htm   iXBRL 10-Q 2231823
2 EX-10.1 fulc-ex10_1.htm EX-10.1 1608455
3 EX-10.2 fulc-ex10_2.htm EX-10.2 4596
4 EX-10.3 fulc-ex10_3.htm EX-10.3 28990
5 EX-31.1 fulc-ex31_1.htm EX-31.1 12235
6 EX-31.2 fulc-ex31_2.htm EX-31.2 12226
7 EX-32.1 fulc-ex32_1.htm EX-32.1 6729
8 EX-32.2 fulc-ex32_2.htm EX-32.2 6168
9 GRAPHIC img3036894_0.jpg GRAPHIC 6067
10 GRAPHIC img3036894_1.jpg GRAPHIC 2981
  Complete submission text file 0000950170-24-088238.txt   10358808

Data Files

Seq Description Document Type Size
11 XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT fulc-20240630.xsd EX-101.SCH 1224485
78 EXTRACTED XBRL INSTANCE DOCUMENT fulc-20240630_htm.xml XML 1400535
Mailing Address 26 LANDSDOWNE STREET CAMBRIDGE MA 02139
Business Address 26 LANDSDOWNE STREET CAMBRIDGE MA 02139 617-651-8851
Fulcrum Therapeutics, Inc. (Filer) CIK: 0001680581 (see all company filings)

IRS No.: 474839948 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-38978 | Film No.: 241159878
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)